auto_awesome
Want to know who else bid on this?
Proposal Forge correlates this contract with the original RFP, the losing bidders, and the next recompete window.
Department
National Research Council CanadaAmount
$8.7M
Province
ABType
Contribution
Agreement Number
172-2021-2022-Q2-976618
Purpose
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Providence Therapeutics Holdings Inc. × National Research Council Canada
8 grants totalling $48.7M
Industrial Research Assistance Program – Contributions to Firms
1,000 grants totalling $112.4M
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Providence Therapeutics Holdings Inc. | $10.0M | Industrial Research Assistance Program –... |